• Users Online: 70
  • Print this page
  • Email this page
Year : 2020  |  Volume : 7  |  Issue : 3  |  Page : 111-115

Efficacy and safety of uracil-tegafur in patients with recurrent or metastatic thymic carcinoma

Division of Hematology Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Taiwan

Correspondence Address:
Dr. Yen- Yang Chen
Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, No. 123, Dapi Rd., Niaosong Dist., Kaohsiung City 833
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JCRP.JCRP_11_20

Rights and Permissions

Background: Thymic carcinoma (TC) is a rare but aggressive thymic epithelial neoplasm, with lymphoepithelioma-like histological features resembling nasopharyngeal carcinoma. Epstein–Barr virus is a known etiology of various tumors, including nasopharyngeal carcinoma, in Asian patients. These patients have a significant response to cisplatin plus 5-fluorouracil (5-FU) combination chemotherapy. Interestingly, this regimen seems to be effective for TC s resembling nasopharyngeal carcinoma. Currently, the standard second-line therapy for advanced TC is uncertain. The use of uracil-tegafur (UFT), a combination of uracil and 5-FU prodrug, has not been reported in literature. We analyzed the effectiveness and toxicity of UFT as an optional regimen for recurrent or metastatic TC. Materials and Methods: This retrospective study enrolled patients verified to have recurrent or metastatic TC and who were treated with UFT between 2017 and 2019 in our hospital. All patients were treated with UFT until disease progression, the patients could no longer tolerate the treatment, or patient refusal. We assessed the safety and efficacy of UFT for TC. Results: Four patients were female and seven were male. The age ranged from 41 to 77 years. The histological features of TC were squamous cell carcinoma and poorly differentiated carcinomas. Grade 3 toxicity occurred in one patient. No treatment-related deaths were observed. Among the 11 patients, 6, 2, and 3 had a partial response, stable disease, and progressive disease, respectively. The objective response rate was 54.5%. The median progression-free survival and overall survival of patients who received UFT chemotherapy were 8.16 months (95% confidence interval [CI]: 0.76–15.56 months) and 19.43 months (95% CI: 17.07–21.78 months), respectively. Conclusion: Single-agent UFT seems to have potential effectiveness and good tolerability in patients with recurrent or advanced TC.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded278    
    Comments [Add]    
    Cited by others 1    

Recommend this journal